LeMaitre Vascular (NASDAQ:LMAT) CEO George Lemaitre Sells 27,881 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 27,881 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

LeMaitre Vascular Trading Down 5.8%

LMAT stock traded down $6.30 during midday trading on Monday, reaching $101.64. The company’s stock had a trading volume of 410,363 shares, compared to its average volume of 209,885. LeMaitre Vascular, Inc. has a 52 week low of $78.35 and a 52 week high of $118.01. The stock has a market cap of $2.32 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The business’s 50-day simple moving average is $110.00 and its 200-day simple moving average is $94.48.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same period last year, the firm earned $0.48 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be paid a $0.25 dividend. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the company. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the first quarter worth $32,000. Bessemer Group Inc. raised its holdings in LeMaitre Vascular by 292.3% in the first quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares during the period. Illumine Investment Management LLC raised its holdings in LeMaitre Vascular by 3.8% in the first quarter. Illumine Investment Management LLC now owns 14,874 shares of the medical instruments supplier’s stock worth $1,624,000 after purchasing an additional 538 shares during the period. Principal Financial Group Inc. raised its holdings in LeMaitre Vascular by 4.3% in the first quarter. Principal Financial Group Inc. now owns 117,840 shares of the medical instruments supplier’s stock worth $12,865,000 after purchasing an additional 4,874 shares during the period. Finally, Hardy Reed LLC acquired a new stake in shares of LeMaitre Vascular during the first quarter worth $254,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on LMAT. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.